Skip to main content
Erschienen in: Journal of Cancer Survivorship 2/2015

01.06.2015

Preventive care receipt and office visit use among breast and colorectal cancer survivors relative to age- and gender-matched cancer-free controls

verfasst von: Jennifer Elston Lafata, Ramzi G. Salloum, Paul A. Fishman, Debra Pearson Ritzwoller, Maureen C. O’Keeffe-Rosetti, Mark C. Hornbrook

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We compare breast and colorectal cancer survivors’ annual receipt of preventive care and office visits to that of age- and gender-matched cancer-free controls.

Methods

Automated data, including tumor registries, were used to identify insured individuals aged 50+ at the time of breast or colorectal cancer diagnosis between 2000 and 2008 as well as cancer-free controls receiving care from four integrated delivery systems. Those with metastatic or un-staged disease, or a prior cancer diagnosis were excluded. Annual visits to primary care, oncology, and surgery as well as receipt of mammography, colorectal cancer, Papanicolaou, bone densitometry, and cholesterol screening were observed for 5 years. We used generalized estimating equations that accounted for repeated observations over time per person to test annual service use differences by cancer survivor/cancer-free control status and whether survivor/cancer-free status associations were moderated by patient age <65 years and calendar year of diagnosis.

Results

A total of 3743 breast and 1530 colorectal cancer survivors were identified, representing 12,923 and 5103 patient-years of follow-up, respectively. Compared to cancer-free controls, breast and colorectal cancer survivors were equally or more likely to use all types of office visits and to receive cancer screenings and bone densitometry testing. Both breast and colorectal cancer survivors were less likely than cancer-free controls to receive cholesterol testing, regardless of age, year of diagnosis, or use of primary care.

Implications for Cancer Survivors

Programs targeting cancer survivors may benefit from addressing a broad range of primary preventive care needs, including recommended cardiovascular disease screening.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
3.
Zurück zum Zitat Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365–71.CrossRefPubMed Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365–71.CrossRefPubMed
4.
Zurück zum Zitat Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prev. 2006;30(1):52–7.CrossRefPubMed Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prev. 2006;30(1):52–7.CrossRefPubMed
5.
Zurück zum Zitat Bellizzi KM et al. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol. 2005;23(34):8884–93.CrossRefPubMed Bellizzi KM et al. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol. 2005;23(34):8884–93.CrossRefPubMed
6.
Zurück zum Zitat Trask PC et al. Cancer screening practices among cancer survivors. Am J Prev Med. 2005;28(4):351–6.CrossRefPubMed Trask PC et al. Cancer screening practices among cancer survivors. Am J Prev Med. 2005;28(4):351–6.CrossRefPubMed
7.
Zurück zum Zitat Findley PA, Sambamoorthi U. Preventive health services and lifestyle practices in cancer survivors: a population health investigation. J Cancer Surviv. 2009;3(1):43–58.CrossRefPubMed Findley PA, Sambamoorthi U. Preventive health services and lifestyle practices in cancer survivors: a population health investigation. J Cancer Surviv. 2009;3(1):43–58.CrossRefPubMed
8.
Zurück zum Zitat Yabroff KR, Machlin SPS, et al. Access to preventive health care for cancer survivors. Am J Prev Med. 2013;45(3):304–12.PubMedCentralCrossRef Yabroff KR, Machlin SPS, et al. Access to preventive health care for cancer survivors. Am J Prev Med. 2013;45(3):304–12.PubMedCentralCrossRef
9.
Zurück zum Zitat Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712–9.CrossRefPubMed Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712–9.CrossRefPubMed
10.
Zurück zum Zitat Earle CC et al. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–51.CrossRefPubMed Earle CC et al. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–51.CrossRefPubMed
11.
Zurück zum Zitat Snyder CF et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24(4):469–74.PubMedCentralCrossRefPubMed Snyder CF et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24(4):469–74.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Snyder CF et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009;27(7):1054–61.CrossRefPubMed Snyder CF et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009;27(7):1054–61.CrossRefPubMed
14.
Zurück zum Zitat Cooper GS et al. The utility of administrative data for measuring adherence to cancer surveillance care guidelines. Med Care. 2007;45(1):66–72.CrossRefPubMed Cooper GS et al. The utility of administrative data for measuring adherence to cancer surveillance care guidelines. Med Care. 2007;45(1):66–72.CrossRefPubMed
15.
Zurück zum Zitat Elston Lafata J et al. Routine surveillance care after cancer treatment with curative intent. Med Care. 2005;43(6):592–9.CrossRefPubMed Elston Lafata J et al. Routine surveillance care after cancer treatment with curative intent. Med Care. 2005;43(6):592–9.CrossRefPubMed
16.
Zurück zum Zitat Lamont EB et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98(18):1335–8.PubMedCentralCrossRefPubMed Lamont EB et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98(18):1335–8.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2011. 154(5): p. 356–64. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2011. 154(5): p. 356–64.
19.
Zurück zum Zitat Salloum RG et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012;118(22):5644–51.PubMedCentralCrossRefPubMed Salloum RG et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012;118(22):5644–51.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Hornbrook MC et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005;35:12–25.CrossRefPubMed Hornbrook MC et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005;35:12–25.CrossRefPubMed
21.
Zurück zum Zitat Klabunde CN et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584–90.CrossRefPubMed Klabunde CN et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584–90.CrossRefPubMed
24.
Zurück zum Zitat Fishman PA et al. The challenge of conducting comparative effectiveness research in cancer: the impact of a fragmented U.S. health-care system. J Natl Cancer Inst Monogr. 2013;2013(46):99–105.PubMedCentralCrossRefPubMed Fishman PA et al. The challenge of conducting comparative effectiveness research in cancer: the impact of a fragmented U.S. health-care system. J Natl Cancer Inst Monogr. 2013;2013(46):99–105.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Fenton JJ et al. Influence of primary care use on population delivery of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2009;18(2):640–5.PubMedCentralCrossRefPubMed Fenton JJ et al. Influence of primary care use on population delivery of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2009;18(2):640–5.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Shires DA et al. Colorectal cancer screening use among insured primary care patients. Am J Manage Care. 2011;17(7):480–8. Shires DA et al. Colorectal cancer screening use among insured primary care patients. Am J Manage Care. 2011;17(7):480–8.
28.
Zurück zum Zitat McCarthy BD et al. Screening mammography use: the importance of a population perspective. Am J Prev Med. 1996;12(2):91–5.PubMed McCarthy BD et al. Screening mammography use: the importance of a population perspective. Am J Prev Med. 1996;12(2):91–5.PubMed
29.
Zurück zum Zitat Snyder CF et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26(7):1073–9.CrossRefPubMed Snyder CF et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26(7):1073–9.CrossRefPubMed
30.
Zurück zum Zitat Hudson SV et al. Adult cancer survivors discuss follow-up in primary care: ‘not what i want, but maybe what i need’. Ann Fam Med. 2012;10(5):418–27.PubMedCentralCrossRefPubMed Hudson SV et al. Adult cancer survivors discuss follow-up in primary care: ‘not what i want, but maybe what i need’. Ann Fam Med. 2012;10(5):418–27.PubMedCentralCrossRefPubMed
31.
Zurück zum Zitat Institute of Medicine, N.R.C.o.t.N.A., From cancer patient to cancer survivor: lost in transition. 2006: Washington DC. Institute of Medicine, N.R.C.o.t.N.A., From cancer patient to cancer survivor: lost in transition. 2006: Washington DC.
Metadaten
Titel
Preventive care receipt and office visit use among breast and colorectal cancer survivors relative to age- and gender-matched cancer-free controls
verfasst von
Jennifer Elston Lafata
Ramzi G. Salloum
Paul A. Fishman
Debra Pearson Ritzwoller
Maureen C. O’Keeffe-Rosetti
Mark C. Hornbrook
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 2/2015
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0401-3

Weitere Artikel der Ausgabe 2/2015

Journal of Cancer Survivorship 2/2015 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.